Cidara Therapeutics (CDTX) Got Higher WBB Securities Rating And $6.2500 Target; Moab Capital Partners Has Raised Its Celgene (CELG) Position

Celgene Corporation (NASDAQ:CELG) Logo

WBB Securities boosted the shares of Cidara Therapeutics (NASDAQ:CDTX) from a Speculative Buy rating to Buy rating in a a research report issued to investors and clients on Wednesday, 4 December. The financial firm now has $6.2500 PT on the stock.

Moab Capital Partners Llc increased Celgene Corp (CELG) stake by 31.98% reported in 2019Q2 SEC filing. Moab Capital Partners Llc acquired 22,419 shares as Celgene Corp (CELG)’s stock declined 3.33%. The Moab Capital Partners Llc holds 92,519 shares with $8.55M value, up from 70,100 last quarter. Celgene Corp now has $77.04 billion valuation. The stock increased 0.10% or $0.11 during the last trading session, reaching $108.24. About 191.23 million shares traded or 2383.95% up from the average. Celgene Corporation (NASDAQ:CELG) has risen 3.32% since December 4, 2018 and is uptrending. It has outperformed by 3.32% the S&P500. Some Historical CELG News: 15/03/2018 – Dynavax Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA® for Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting; 16/04/2018 – OVERALL RESPONSE RATE 45.3 PCT FOR OPDIVO PLUS YERVOY VS 27 PCT FOR CHEMOTHERAPY – DATA; 29/05/2018 – DEADLINE TODAY: The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG); 30/05/2018 – DENALI REPORTS EARLY EXERCISE OF OPTION TO BUY F-STAR GAMMA; 24/05/2018 – CELGENE CORP – PLANNED ASR WILL UTILIZE PART OF EXISTING BOARD AUTHORIZED SHARE REPURCHASE PROGRAM AS WELL AS PART OF NEW AUTHORIZATION; 16/05/2018 – Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncolog; 10/04/2018 – BerGenBio Completes Recruitment Into First Stage of Phase Il NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA®; 23/05/2018 – Merck: Keytruda Has Shown Improved Survival Benefit in Advanced NSCLC in Five Phase 3 Trials; 01/05/2018 – Merck Boosts Outlook as Keytruda Sales Surpass Diabetes Drugs; 19/04/2018 – Celgene: Hans Bishop Elected to Bd of Directors

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. The company has market cap of $83.43 million. The Company’s lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious, invasive fungal infections. It currently has negative earnings. The firm also develops CD201, a novel bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant gram-negative bacterial infections, including those caused by pathogens harboring the mcr-1 plasmid.

More notable recent Cidara Therapeutics, Inc. (NASDAQ:CDTX) news were published by: Globenewswire.com which released: “Cidara Therapeutics to Present at Two Upcoming Medical Conferences – GlobeNewswire” on December 03, 2019, also Benzinga.com with their article: “Benzinga’s Top Upgrades, Downgrades For December 4, 2019 – Benzinga” published on December 04, 2019, Seekingalpha.com published: “Raymond James likes Zimmer Biomet in premarket analyst action – Seeking Alpha” on December 04, 2019. More interesting news about Cidara Therapeutics, Inc. (NASDAQ:CDTX) were released by: Globenewswire.com and their article: “Cidara Provides Corporate Update and Reports Third Quarter 2019 Financial Results – GlobeNewswire” published on November 07, 2019 as well as Globenewswire.com‘s news article titled: “Cidara Therapeutics Hosting Key Opinion Leader Meeting on Rezafungin and Cloudbreak Programs – GlobeNewswire” with publication date: November 05, 2019.

Analysts await Cidara Therapeutics, Inc. (NASDAQ:CDTX) to report earnings on February, 27. They expect $-0.22 earnings per share, up 50.00% or $0.22 from last year’s $-0.44 per share. After $0.08 actual earnings per share reported by Cidara Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -375.00% negative EPS growth.

The stock increased 6.99% or $0.165 during the last trading session, reaching $2.525. About 402,113 shares traded or 81.88% up from the average. Cidara Therapeutics, Inc. (NASDAQ:CDTX) has declined 65.37% since December 4, 2018 and is downtrending. It has underperformed by 65.37% the S&P500. Some Historical CDTX News: 19/03/2018 – Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin; 21/03/2018 – CIDARA THERAPEUTICS PROVIDES CLINICAL DATA FOR REZAFUNGIN; 19/03/2018 – CIDARA THERAPEUTICS INC – STRIVE MET ALL OF ITS PRIMARY OBJECTIVES; 23/05/2018 – Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara’s Rezafungin for the Treatment of; 21/05/2018 – Cidara: Grant to Support Development of Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections; 29/05/2018 – Rounds Report: TransEnterix Rallied While Cidara Enjoyed Significant Insider Purchases; 19/03/2018 – CIDARA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE; 21/03/2018 – Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin; 21/03/2018 – CDTX: STRIVE PHASE 2 CLINICAL TRIAL CONFIRM POSITIVE EFFICACY; 19/03/2018 – CIDARA THERAPEUTICS-THERE WERE 2 SERIOUS ADVERSE EVENTS POSSIBLY RELATED TO STUDY DRUG: ONE IN GROUP 2, ONE IN GROUP 3; BOTH PATIENTS FULLY RECOVERED

Investors sentiment increased to 0.67 in 2019 Q2. Its up 0.12, from 0.55 in 2019Q1. It is positive, as 97 investors sold CELG shares while 443 reduced holdings. 83 funds opened positions while 216 raised stakes. 466.35 million shares or 3.39% less from 482.72 million shares in 2019Q1 were reported. Kbc Grp Inc Nv holds 0.32% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 446,603 shares. Whittier Co, a California-based fund reported 58,062 shares. Gibraltar Cap Mgmt, a Oklahoma-based fund reported 10,566 shares. Viking Fund Llc accumulated 5,000 shares. The Connecticut-based Massmutual Trust Communication Fsb Adv has invested 0% in Celgene Corporation (NASDAQ:CELG). Moreover, Ruffer Llp has 6.73% invested in Celgene Corporation (NASDAQ:CELG) for 3.12 million shares. Commerzbank Aktiengesellschaft Fi reported 0.23% stake. Greatmark Invest Prtn owns 3,850 shares. Calamos Limited has invested 0.12% of its portfolio in Celgene Corporation (NASDAQ:CELG). Tci Wealth reported 1,379 shares or 0.06% of all its holdings. 29,000 are owned by Amer Assets Inv Limited. Suntrust Banks Inc invested in 719,403 shares. 52,944 are owned by One Trading Lp. Money Mngmt Ltd Liability Corporation stated it has 11,885 shares. Falcon Edge Capital LP accumulated 963,800 shares.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “Here’s Why Editas Medicine Jumped 45.3% in November – Nasdaq” on December 04, 2019, also Nasdaq.com with their article: “Bristol-Myers Gets FTC Clearance for Celgene Acquisition – Nasdaq” published on November 18, 2019, Nasdaq.com published: “Celgene (CELG) Hits 52-Week High, Can the Run Continue? – Nasdaq” on November 11, 2019. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Nasdaq.com and their article: “3 Reasons Why Celgene (CELG) Is a Great Growth Stock – Nasdaq” published on November 06, 2019 as well as Nasdaq.com‘s news article titled: “Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug – Nasdaq” with publication date: November 15, 2019.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.